Abstract
Wear particle-induced inflammatory osteolysis is the major cause of aseptic loosening after total joint replacement. The predominant cell type within periprosthetic tissues is macrophages. We investigate the anti-inflammatory effects of the proteasome inhibitor bortezomib (Bzb) on murine macrophage-like RAW 264.7 cells stimulated with titanium (Ti) particles. RAW 264.7 cells were cultured with 1 nM Bzb and 0.1 mg/ml Ti particles for 48 h; cells without Ti and Bzb or without Bzb were used as negative and loading controls. Results showed that the expression of inflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-10), chemokines [monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1α)], and inflammatory enzymes [inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2)] increased in RAW 264.7 cells cultured with Ti. Bzb treatment significantly reduced the expression of TNF-α, IL-1β, IL-6, MCP-1, MIP-1α, iNOS, and COX-2 and induced the expression of IL-10 in a time-dependent manner. These results suggest that Bzb inhibits Ti-induced inflammation in macrophages, and provide a promising therapeutic target for treating or preventing aseptic loosening.
Similar content being viewed by others
REFERENCES
Ingham, E., and J. Fisher. 2005. The role of macrophages in osteolysis of total joint replacement. Biomaterials 26(11): 1271–1286.
Berry, D., W. Harmsen, M. Cabanela, and B. Morrey. 2002. Twenty-five-year survivorship of two thousand consecutive primary Charnley total hip replacements: Factors affecting survivorship of acetabular and femoral components. The Journal of Bone and Joint Surgery. American Volume 84(2): 171–177.
Sundfeldt, M., L.V. Carlsson, C.B. Johansson, P. Thomsen, and C. Gretzer. 2006. Aseptic loosening, not only a question of wear: A review of different theories. Acta Orthopaedica 77(2): 177–197.
Ren, W., D. Markel, R. Schwendener, Y. Ding, B. Wu, and P. Wooley. 2008. Macrophage depletion diminishes implant-wear-induced inflammatory osteolysis in a mouse model. Journal of Biomedical Materials Research. Part A 85(4): 1043–1051.
Sabokbar, A., O. Kudo, and N. Athanasou. 2003. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. Journal of Orthopaedic Research 21(1): 73–80.
Wang, C.T., Y.T. Lin, B.L. Chiang, S.S. Lee, and S.M. Hou. 2010. Over-expression of receptor activator of nuclear factor-[kappa] B ligand (RANKL), inflammatory cytokines, and chemokines in periprosthetic osteolysis of loosened total hip arthroplasty. Biomaterials 31(1): 77–82.
Im, G.I., and J.D. Han. 2001. Suppressive effects of interleukin‐4 and interleukin‐10 on the production of proinflammatory cytokines induced by titanium‐alloy particles. Journal of Biomedical Materials Research 58(5): 531–536.
Sabat, R., G. Grütz, K. Warszawska, S. Kirsch, E. Witte, K. Wolk, and J. Geginat. 2010. Biology of interleukin-10. Cytokine & Growth Factor Reviews 21(5): 331–344.
Fritz, E.A., T.T. Glant, C. Vermes, J.J. Jacobs, and K.A. Roebuck. 2006. Chemokine gene activation in human bone marrow‐derived osteoblasts following exposure to particulate wear debris. Journal of Biomedical Materials Research. Part A 77(1): 192–201.
Huang, Z., T. Ma, P.G. Ren, R.L. Smith, and S.B. Goodman. 2010. Effects of orthopedic polymer particles on chemotaxis of macrophages and mesenchymal stem cells. Journal of Biomedical Materials Research. Part A 94(4): 1264–1269.
Hukkanen, M., S. Corbett, J. Batten, Y. Konttinen, I. McCarthy, J. Maclouf, S. Santavirta, S. Hughes, and J. Polak. 1997. Aseptic loosening of total hip replacement: Macrophage expression of inducible nitric oxide synthase and cyclo-oxygenase-2, together with peroxynitrite formation, as a possible mechanism for early prosthesis failure. Journal of Bone and Joint Surgery 79(3): 467–474.
Elliott, P.J., and J.S. Ross. 2001. The proteasome. American Journal of Clinical Pathology 116(5): 637–646.
Bedford, L., S. Paine, P.W. Sheppard, R.J. Mayer, and J. Roelofs. 2010. Assembly, structure, and function of the 26S proteasome. Trends in Cell Biology 20(7): 391–401.
Elliott, P.J., T.M. Zollner, and W.H. Boehncke. 2003. Proteasome inhibition: A new anti-inflammatory strategy. Journal of Molecular Medicine 81(4): 235–245.
Richardson, P.G., B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S.V. Rajkumar, G. Srkalovic, M. Alsina, and R. Alexanian. 2003. A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine 348(26): 2609–2617.
Yannaki, E., A. Papadopoulou, E. Athanasiou, P. Kaloyannidis, A. Paraskeva, D. Bougiouklis, P. Palladas, M. Yiangou, and A. Anagnostopoulos. 2010. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant‐induced arthritis in rats. Arthritis and Rheumatism 62(11): 3277–3288.
Lee, S.W., J.H. Kim, Y.B. Park, and S.K. Lee. 2009. Bortezomib attenuates murine collagen-induced arthritis. Annals of the Rheumatic Diseases 68(11): 1761–1767.
Rakshit, D., K. Ly, T. Sengupta, B. Nestor, T. Sculco, L. Ivashkiv, and P. Purdue. 2006. Wear debris inhibition of anti-osteoclastogenic signaling by interleukin-6 and interferon-gamma. Mechanistic insights and implications for periprosthetic osteolysis. The Journal of Bone and Joint Surgery. American Volume 88(4): 788–799.
Sethi, R.K., M.J. Neavyn, H.E. Rubash, and A.S. Shanbhag. 2003. Macrophage response to cross-linked and conventional UHMWPE. Biomaterials 24(15): 2561–2573.
Lee, S., C. Woo, J. Chang, and J. Kim. 2003. Roles of Rac and cytosolic phospholipase A2 in the intracellular signalling in response to titanium particles. Cellular Signalling 15(3): 339–345.
Möller, B., and P.M. Villiger. 2006. Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases. Springer Seminars in Immunopathology 27(4): 391–408.
Horai, R., S. Saijo, H. Tanioka, S. Nakae, K. Sudo, A. Okahara, T. Ikuse, M. Asano, and Y. Iwakura. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist–deficient mice. The Journal of Experimental Medicine 191(2): 313–320.
Caicedo, M., J.J. Jacobs, and N.J. Hallab. 2010. Inflammatory bone loss in joint replacements: The mechanisms. Journal Musculoskeletal Medicine 27: 209–216.
Baumann, H., and J. Gauldie. 1994. The acute phase response. Immunology Today 15(2): 74–80.
Suzuki, Y., T. Nishiyama, K. Hasuda, T. Fujishiro, T. Niikura, S. Hayashi, S. Hashimoto, and M. Kurosaka. 2007. Effect of etidronate on COX-2 expression and PGE 2 production in macrophage-like RAW 264.7 cells stimulated by titanium particles. Journal of Orthopaedic Science 12(6): 568–577.
Ragab, A.A., J.L. Nalepka, Y. Bi, and E.M. Greenfield. 2002. Cytokines synergistically induce osteoclast differentiation: Support by immortalized or normal calvarial cells. American Journal of Physiology. Cell Physiology 283(3): C679–C687.
Goodman, S.B., and T. Ma. 2010. Cellular chemotaxis induced by wear particles from joint replacements. Biomaterials 31(19): 5045–5050.
Harris, S.G., J. Padilla, L. Koumas, D. Ray, and R.P. Phipps. 2002. Prostaglandins as modulators of immunity. Trends in Immunology 23(3): 144–150.
Steeve, K.T., P. Marc, T. Sandrine, H. Dominique, and F. Yannick. 2004. IL-6, RANKL, TNF-alpha/IL-1: Interrelations in bone resorption pathophysiology. Cytokine & Growth Factor Reviews 15(1): 49–60.
Krakauer, T. 2004. Molecular therapeutic targets in inflammation: Cyclooxygenase and NF-kappaB. Current Drug Targets. Inflammation and Allergy 3(3): 317–324.
Smallie, T., G. Ricchetti, N.J. Horwood, M. Feldmann, A.R. Clark, and L.M. Williams. 2010. IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages. The Journal of Experimental Medicine 207(10): 2081–2088.
Lentsch, A.B., T.P. Shanley, V. Sarma, and P.A. Ward. 1997. In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. The Journal of Clinical Investigation 100(10): 2443–2448.
Su, Y.W., W.F. Chiou, S.H. Chao, M.H. Lee, C.C. Chen, and Y.C. Tsai. 2011. Ligustilide prevents LPS-induced iNOS expression in RAW 264.7 macrophages by preventing ROS production and down-regulating the MAPK, NF-kappaB and AP-1 signaling pathways. International Immunopharmacology 11(9): 1166–1172.
Goldberg, A. 2007. Functions of the proteasome: From protein degradation and immune surveillance to cancer therapy. Biochemical Society Transactions 35: 12–17.
ACKNOWLEDGMENTS
This work was supported by the National Natural Science Foundation of China (NSFC, no. 81171688) and the Integration of Medicine and Engineering Foundation of Shanghai Jiaotong University (YG2010MS33).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mao, X., Pan, X., Peng, X. et al. Inhibition of Titanium Particle-Induced Inflammation by the Proteasome Inhibitor Bortezomib in Murine Macrophage-Like RAW 264.7 Cells. Inflammation 35, 1411–1418 (2012). https://doi.org/10.1007/s10753-012-9454-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-012-9454-5